Breast Cancer | Pharmacor | US/EU5 | 2015

Last Updated 29 October 2015
The treatment of breast cancer has a rich and diverse product pipeline and continues to be one of the most lucrative and active areas of research in oncology. However, the barriers to entry are high, owing to the well-established and effective therapies already available. Treatment is based on hormone receptor and HER2 expression, and successful therapies are often tailored to specific subpopulations. Substantial unmet need remains in the treatment of triple-negative breast cancer, for which no targeted therapy is approved.

Login to access report